Evaluation of Amyloid Imaging in Patients with Parkinson's disease
Not Applicable
- Conditions
- Parkinson disease
- Registration Number
- JPRN-UMIN000018035
- Lead Sponsor
- Department of Neurology, Keio University School of Medicine
- Brief Summary
We report that PD without dementia shows an extremely low prevalence of beta Amyloid positivity compared to findings in cognitively normal elderly controls. Further longitudinal imaging studies and long-term follow-up of cognitive function are needed; however, our findings provide novel insights for a deeper understanding of beta Amyloid metabolism and deposition in PD.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
disaggrement
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Parkinson disease who have abnormal metabolism on positive amyloid PET (stage 2 preclinical AD) and those who have abnormal metabolism on an FDG-PET scan and normal amyloid PET (which may represent non-preclinical AD but suggest other neurological disease) will be monitored for a long term to assess changes in clinical features and cognitive function over time.
- Secondary Outcome Measures
Name Time Method